Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CAO Ryan M. Bartolucci sold 339 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $40.23, for a total value of $13,637.97. Following the completion of the sale, the chief accounting officer now owns 71,007 shares of the company’s stock, valued at $2,856,611.61. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Tempus AI Stock Performance
Shares of TEM stock opened at $33.03 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The business’s 50-day simple moving average is $51.96. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49.
Hedge Funds Weigh In On Tempus AI
Hedge funds have recently made changes to their positions in the company. First Horizon Advisors Inc. acquired a new position in Tempus AI during the third quarter valued at $30,000. Sandia Investment Management LP purchased a new stake in shares of Tempus AI in the second quarter worth about $136,000. Vestor Capital LLC acquired a new position in Tempus AI in the third quarter valued at approximately $153,000. Stifel Financial Corp purchased a new position in shares of Tempus AI during the 3rd quarter valued at approximately $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in shares of Tempus AI in the 3rd quarter valued at $258,000. 24.22% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
View Our Latest Analysis on TEM
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Stories
- Five stocks we like better than Tempus AI
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Beyond Reality: Investing in AR/VR Tech for Future Gains
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Palantir’s Momentum Persists Despite Market Worries
- What Are Growth Stocks and Investing in Them
- Ad Sales to Top $1 Trillion: 3 Stocks to Take Advantage
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.